Laino, Andressa S
Woods, David http://orcid.org/0000-0002-6328-8107
Vassallo, Melinda
Qian, Xiaozhong
Tang, Hao
Wind-Rotolo, Megan
Weber, Jeffrey
Clinical trials referenced in this document:
Documents that mention this clinical trial
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
https://doi.org/10.1136/jitc-2020-000842
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
https://doi.org/10.1136/jitc-2022-sitc2022.0608
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
https://doi.org/10.1136/jitc-2019-000234
Documents that mention this clinical trial
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
https://doi.org/10.1016/j.ejca.2013.06.027
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
https://doi.org/10.1136/jitc-2020-000842
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
https://doi.org/10.1136/jitc-2022-sitc2022.0608
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
https://doi.org/10.1016/j.clinthera.2015.02.018
Documents that mention this clinical trial
387 The utility of AI-powered spatial classification of intratumoral CD8+ immune-cell distribution in predicting overall survival in patients with melanoma as part of the checkMate 067 clinical trial
https://doi.org/10.1136/jitc-2021-sitc2021.387
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
https://doi.org/10.1016/j.ejca.2013.06.027
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.
https://doi.org/10.1200/jco.2023.41.16_suppl.9542
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
https://doi.org/10.1136/jitc-2020-000842
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial
https://doi.org/10.1136/jitc-2023-008372
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
https://doi.org/10.1136/jitc-2022-sitc2022.0608
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
https://doi.org/10.1136/jitc-2021-003743
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
https://doi.org/10.1016/j.clinthera.2015.02.018
Documents that mention this clinical trial
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
https://doi.org/10.1136/jitc-2020-000878
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
https://doi.org/10.1136/jitc-2020-000842
Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
https://doi.org/10.1136/jitc-2020-001996
816 Selective immune suppression using interleukin-6 blockade in immune related adverse events
https://doi.org/10.1136/jitc-2021-sitc2021.816
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007310
Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
https://doi.org/10.1136/rmdopen-2022-002612
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
https://doi.org/10.1136/jitc-2020-001145
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
https://doi.org/10.1136/jitc-2019-000234
Funding for this research was provided by:
National Cancer Institute (K99/R00 CA230201-01, R01 CA175732-01)